present
studi
investig
longterm
impact
antibiot
use
polici
rate
consumpt
express
dailydefin
patientday
variou
parenter
antibiot
preval
methicillinresist
staphylococcu
aureu
mrsa
incid
healthcareassoci
mrsa
hamrsa
infect
tertiari
care
hospit
time
consumpt
antimicrobi
system
use
decreas
chang
driven
decreas
consumpt
unrestrict
antibacteri
offset
increas
consumpt
restrict
agent
trend
mrsa
preval
number
patientday
hamrsa
incid
number
hamrsainfect
patientday
correl
trend
overal
consumpt
antimicrobi
signific
posit
correl
observ
mrsa
preval
consumpt
extendedspectrum
penicillin
firstgener
cephalosporin
macrolid
lincosamid
streptogramin
aminoglycosid
glycopeptid
signific
posit
correl
found
incid
hamrsa
infect
consumpt
tetracyclin
extendedspectrum
penicillin
sulfonamid
trimethoprim
macrolid
lincosamid
streptogramin
aminoglycosid
conclus
document
ongo
success
reduct
total
consumpt
antimicrobi
associ
decreas
incid
hamrsa
preval
mrsa
period
antimicrobi
resist
increas
rapidli
last
year
becom
global
health
issu
relationship
consumpt
antibiot
antimicrobi
resist
wide
document
use
support
implement
antimicrobi
control
polici
taiwan
healthcareassoci
methicillinresist
staphylococcu
aureu
hamrsa
caus
lifethreaten
infect
becom
endem
hospit
govern
polici
restrict
use
antibiot
establish
bureau
nation
health
insur
bnhi
implement
taiwan
studi
evalu
shortterm
relationship
consumpt
antibiot
antimicrobi
resist
taiwan
hospit
implement
polici
report
describ
longterm
studi
impact
polici
rate
consumpt
variou
parenter
antibiot
incid
hamrsa
infect
preval
mrsa
period
medic
centr
central
taiwan
chung
medic
univers
csmu
hospit
tertiari
care
univers
hospit
taichung
central
taiwan
infect
control
practic
csmu
studi
period
standardis
accord
guidelin
nosocomi
infect
control
societi
taiwan
nicst
taiwan
center
diseas
control
cdc
guidelin
http
wwwcdcgovtwnpasp
access
hospit
taiwan
briefli
hospit
distribut
implement
infect
control
manual
specif
protocol
prevent
infect
variou
rout
eg
airborn
droplet
analys
incid
infect
mrsa
multidrugresist
infect
perform
activ
surveil
report
notifi
infecti
diseas
isol
patient
perform
surveil
screen
healthcar
worker
hcw
train
hcw
appropri
use
person
protect
equip
provid
continu
educ
programm
hcw
promot
hand
hygien
analys
use
antibiot
present
workshop
appropri
use
antibiot
adopt
measur
control
monitor
review
antibiot
use
describ
follow
epidem
sever
acut
respiratori
syndrom
sar
taiwan
cdc
awar
import
nosocomi
infect
control
implement
nosocomi
infect
control
region
assist
plan
medic
servic
qualiti
improv
plan
commiss
nicst
taiwan
joint
commiss
hospit
accredit
tjcha
csmu
audit
complianc
infect
control
measur
taiwan
cdc
tjcha
hospit
secur
accredit
level
medic
centr
wellestablish
antibiot
control
polici
csmu
although
prescript
restrict
antibiot
requir
prior
authoris
infecti
diseas
specialist
idss
antibiot
freeli
prescrib
without
document
indic
limit
durat
use
csmu
infect
control
committe
depart
pharmaci
establish
new
antibiot
use
polici
follow
provis
restrict
unrestrict
antimicrobi
clearli
classifi
restrict
antimicrobi
includ
inhibitor
penicillin
plu
inhibitor
combin
sulbactam
sodium
ampicillinsulbactam
inject
amoxicillinclavulan
acid
inject
piperacillintazobactam
secondgener
cephalosporin
cefuroxim
cefmetazol
thirdgener
cephalosporin
cefotaxim
ceftazidim
ceftriaxon
cefoperazon
flomoxef
fourthgener
cephalosporin
cefepim
cefpirom
carbapenem
ertapenem
meropenem
imipenemcilastatin
aminoglycosid
amikacin
isepamicin
fluoroquinolon
ciprofloxacin
levofloxacin
moxifloxacin
glycopeptid
vancomycin
teicoplanin
linezolid
tigecyclin
daptomycin
furthermor
indic
use
restrict
antimicrobi
becam
regul
bnhi
taiwan
three
import
new
regul
restrict
antimicrobi
use
implement
inappropri
prophylact
use
antibiot
surgeri
discourag
exampl
limit
durat
antibiot
therapi
day
clean
surgeri
eg
total
hip
replac
total
knee
replac
coronari
arteri
bypass
graft
antimicrobi
agent
use
treatment
upper
respiratori
tract
infect
restrict
guidelin
use
antimicrobi
agent
taiwan
freeli
download
http
wwwejmiicomguidelinesphp
use
refer
csmu
role
idss
make
bedsid
consult
provid
authoris
establish
furthermor
prescript
restrict
antibiot
requir
authoris
id
criteria
defin
need
consult
authoris
id
includ
use
restrict
antibiot
use
two
differ
class
antibiot
use
antibiot
longer
day
well
request
assess
appropri
antibiot
use
role
idss
antibiot
use
programm
crucial
idss
assess
appropri
use
antimicrobi
provid
recommend
accord
patient
clinic
symptom
sign
diagnosi
liver
renal
function
comorbid
cultur
suscept
test
adher
guidelin
use
antimicrobi
agent
taiwan
inappropri
use
antimicrobi
discontinu
idss
permit
appropri
antibiot
agent
day
assess
consent
data
annual
consumpt
oral
intraven
antibiot
csmu
collect
comput
databas
pharmaci
depart
antibiot
consumpt
standardis
use
defin
daili
dose
ddd
establish
world
health
organ
atcddd
index
preval
mrsa
obtain
clinic
microbiolog
laboratori
csmu
healthcareassoci
isol
hai
defin
accord
criteria
establish
cdc
data
relev
hai
csmu
obtain
hospit
infect
control
committe
mrsa
isol
nondupl
sampl
duplic
isol
defin
isol
speci
bacteria
antimicrobi
suscept
pattern
isol
patient
site
within
month
suscept
test
perform
disk
diffus
method
interpret
accord
clinic
laboratori
standard
institut
clsi
guidelin
consumpt
restrict
unrestrict
antibiot
summaris
patientday
pd
spearman
correl
coeffici
determin
correl
mrsa
preval
incid
hamrsa
infect
versu
antibiot
consumpt
statist
hypothesi
test
set
signific
level
statist
analys
perform
use
spss
spss
inc
chicago
il
total
ddd
antibiot
consum
per
pd
decreas
first
year
follow
implement
new
poli
tabl
trend
consumpt
unrestrict
antibiot
similar
overal
consumpt
fig
tabl
consumpt
restrict
antibiot
stabl
also
increas
tabl
correl
antibiot
consumpt
incid
healthcareassoci
methicillin
fig
tabl
use
restrict
antibiot
decreas
continu
began
increas
slightli
thereaft
trend
preval
mrsa
defin
number
pd
similar
trend
overal
consumpt
antibiot
fig
tabl
although
signific
correl
total
consumpt
antibiot
categori
system
use
incid
hamrsa
tabl
consumpt
unrestrict
antibiot
significantli
posit
correl
incid
hamrsa
infect
p
tabl
addit
signific
posit
correl
found
incid
hamrsa
infect
consumpt
follow
individu
unr
atc
anatom
therapeut
chemic
ddd
defin
daili
dose
pd
patientday
flomoxef
thirdgener
cephalosporin
atc
code
world
health
organ
definit
ddd
present
packag
g
per
vial
normal
adult
dosag
g
everi
h
patient
normal
renal
function
henc
daili
dosag
g
preemptiv
defin
ddd
flomoxef
g
p
indic
confid
interv
spearman
correl
coeffici
includ
zero
resist
isol
suscept
isol
total
isol
tabl
ddd
defin
daili
dose
pd
patientday
signific
posit
correl
consumpt
antibiot
mrsa
preval
p
tabl
addit
signific
posit
correl
mrsa
preval
consumpt
follow
individu
class
antibiot
penicillin
extend
spectrum
p
penicillin
p
firstgener
cephalosporin
p
macrolid
lincosamid
streptogramin
p
macrolid
p
aminoglycosid
p
glycopeptid
p
consumpt
follow
restrict
antibiot
significantli
posit
correl
mrsa
preval
ceftazidim
p
ceftriaxon
p
cefepim
p
meropenem
p
amikacin
p
tabl
contrast
consumpt
daptomycin
signific
neg
correl
hamrsa
preval
p
consumpt
unrestrict
antibiot
display
significantli
posit
correl
mrsa
preval
p
tabl
consumpt
follow
individu
unrestrict
antibiot
amoxicillin
p
cefalexin
monohydr
p
cefazolin
p
erythromycin
p
gentamicin
sulphat
p
restrict
polici
antibiot
use
adopt
csmu
sever
ongo
effect
antibiot
consumpt
consumpt
antibacteri
system
use
decreas
driven
primarili
decreas
consumpt
unrestrict
antibacteri
offset
increas
consumpt
restrict
agent
pattern
antibacteri
use
also
chang
frequent
use
class
antibacteri
antibacteri
predominantli
cephalosporin
tetracyclin
antibiot
penicillin
antibacteri
still
use
often
use
penicillin
greatli
outpac
tetracyclin
owe
larg
decreas
consumpt
tetracyclin
increas
use
combin
penicillin
class
rel
larg
chang
use
includ
lincosamid
decreas
macrolid
decreas
aminoglycosid
decreas
sulfonamid
trimethoprim
decreas
simultan
chang
observ
incid
hamrsa
preval
mrsa
proport
patient
infect
aureu
strain
methicillin
resist
hamrsa
incid
proport
isol
resist
mrsa
preval
number
patient
infect
hamrsa
per
total
number
pd
infect
densiti
declin
preval
mrsa
significantli
posit
correl
decreas
total
antibiot
use
result
gener
agreement
numer
investig
shown
correl
preval
antibioticresist
bacteria
antibiot
use
mackenzi
et
al
observ
strong
statist
relationship
macrolid
use
mrsa
preval
well
signific
associ
use
cephalosporin
antimicrobi
agent
except
glycopeptid
studi
european
hospit
taiwan
one
univers
hospit
report
signific
correl
preval
mrsa
vancomycinresist
enterococci
increas
consumpt
glycopeptid
inhibitor
combin
extendedspectrum
cephalosporin
carbapenem
fluoroquinolon
found
specif
antibiot
consumpt
posit
correl
mrsa
preval
includ
penicillin
extend
spectrum
penicillin
firstgener
cephalosporin
macrolid
lincosamid
streptogramin
aminoglycosid
glycopeptid
recent
investig
associ
use
antibiot
incid
mrsa
german
hospit
kaier
et
al
found
signific
correl
use
secondand
thirdgener
cephalosporin
fluoroquinolon
lincosamid
gener
trend
incid
hamrsa
similar
observ
preval
mrsa
although
observ
trend
toward
decreas
incid
hamrsa
infect
correspond
decreas
total
antibacteri
use
reach
statist
signific
howev
specif
differ
appar
incid
hamrsa
infect
preval
posit
correl
use
tetracyclin
ampicillin
exampl
correl
incid
hamrsa
infect
use
firstgener
cephalosporin
reach
signific
although
correl
preval
signific
polici
restrict
use
antibiot
hospit
wide
adopt
past
decad
although
extent
reduct
vari
specif
provis
differ
polici
report
gener
success
reduc
consumpt
antibiot
hospit
itali
report
overal
decreas
antibiot
use
first
year
follow
adopt
antibiot
control
programm
hospit
taiwan
adopt
polici
similar
report
declin
pd
parenter
antimicrobi
immedi
implement
novel
featur
studi
span
period
follow
implement
antimicrobi
control
polici
allow
evalu
extent
provis
follow
time
particularli
import
light
find
studi
investig
relationship
antimicrobi
control
polici
antimicrobi
resist
rate
hospit
usa
author
report
found
hospit
antibiot
use
polici
correl
exist
antibiot
use
polici
resist
rate
evid
polici
actual
practic
hospit
adopt
imposs
conclud
whether
polici
effect
studi
data
antibiot
consumpt
mrsa
preval
incid
hamrsa
infect
stand
obviou
anomali
key
event
occur
year
may
explain
anomal
data
epidem
sar
began
mid
march
taiwan
last
almost
month
time
signific
reduct
utilis
inpati
care
observ
probabl
individu
fear
becom
expos
viru
hospit
clinic
specul
fear
may
led
bia
toward
serious
ill
individu
seek
health
care
period
may
distort
baselin
characterist
inpati
popul
csmu
cohort
serious
ill
patient
might
driven
consumpt
antibiot
noteworthi
incid
hamrsa
infect
preval
mrsa
continu
mirror
use
antibiot
time
retrospect
studi
three
noteworthi
limit
first
studi
conduct
singl
centr
find
might
reflect
overal
situat
taiwan
second
reduct
hamrsa
infect
rate
csmu
might
due
factor
rather
polici
antibiot
restrict
alon
studi
molecular
epidemiolog
mrsa
isol
obtain
studi
period
requir
delin
possibl
decreas
clonal
spread
isol
caus
improv
infect
control
measur
final
evalu
antibiot
usag
time
seri
therefor
comment
lag
period
signific
immedi
sustain
effect
intervent
conclus
provid
data
document
ongo
success
reduct
total
antibiot
consumpt
period
hospit
taiwan
overal
reduct
correl
preval
mrsa
reduct
individu
antibacteri
significantli
posit
correl
decreas
incid
hamrsa
infect
fund
studi
support
chung
medic
univers
hospit
taichung
taiwan
grant
compet
interest
none
declar
ethic
approv
requir
